Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

A Novel Na+-K+-Cl- Cotransporter 1 Inhibitor STS66* Reduces Brain Damage in Mice After Ischemic Stroke.

Huang H, Bhuiyan MIH, Jiang T, Song S, Shankar S, Taheri T, Li E, Schreppel P, Hintersteininger M, Yang SS, Lin SH, Molyneaux BJ, Zhang Z, Erker T, Sun D.

Stroke. 2019 Apr;50(4):1021-1025. doi: 10.1161/STROKEAHA.118.024287.

PMID:
30862257
2.

The role of oxidative stress in 63 T-induced cytotoxicity against human lung cancer and normal lung fibroblast cell lines.

Kucinska M, Mieszczak H, Piotrowska-Kempisty H, Kaczmarek M, Granig W, Murias M, Erker T.

Invest New Drugs. 2018 Nov 29. doi: 10.1007/s10637-018-0704-8. [Epub ahead of print]

PMID:
30498945
3.

Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain.

Römermann K, Fedrowitz M, Hampel P, Kaczmarek E, Töllner K, Erker T, Sweet DH, Löscher W.

Neuropharmacology. 2017 May 1;117:182-194. doi: 10.1016/j.neuropharm.2017.02.006. Epub 2017 Feb 10.

PMID:
28192112
4.

Selective anticancer activity of the novel thiobenzanilide 63T against human lung adenocarcinoma cells.

Kucinska M, Piotrowska-Kempisty H, Lisiak N, Kaczmarek M, Dams-Kozlowska H, Granig WH, Höferl M, Jäger W, Zehl M, Murias M, Erker T.

Toxicol In Vitro. 2016 Dec;37:148-161. doi: 10.1016/j.tiv.2016.09.017. Epub 2016 Sep 19.

PMID:
27660182
5.

A Novel Genistein Prodrug: Design, Synthesis and Bioactivity on Mouse RAW264.7 Macrophages.

Kloesch B, Loebsch S, Breitenbach J, Goldhahn K, Handler N, Schreppel P, Erker T.

Nat Prod Commun. 2016 Oct;11(10):1437-1440.

PMID:
30549594
6.

The search for NKCC1-selective drugs for the treatment of epilepsy: Structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A.

Lykke K, Töllner K, Feit PW, Erker T, MacAulay N, Löscher W.

Epilepsy Behav. 2016 Jun;59:42-9. doi: 10.1016/j.yebeh.2016.03.021. Epub 2016 Apr 15.

PMID:
27088517
7.

The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice.

Erker T, Brandt C, Töllner K, Schreppel P, Twele F, Schidlitzki A, Löscher W.

Epilepsia. 2016 May;57(5):698-705. doi: 10.1111/epi.13346. Epub 2016 Feb 27.

8.

Antiproliferative and Pro-apoptotic Activities of a Novel Resveratrol Prodrug Against Jurkat CD4+ T-Cells.

Goldhahn K, Handler N, Loebsch S, Schmetterer K, Steiner G, Kloesch B, Erker T.

Anticancer Res. 2016 Feb;36(2):683-9.

PMID:
26851025
9.

Novel Promising Estrogenic Receptor Modulators: Cytotoxic and Estrogenic Activity of Benzanilides and Dithiobenzanilides.

Kucinska M, Giron MD, Piotrowska H, Lisiak N, Granig WH, Lopez-Jaramillo FJ, Salto R, Murias M, Erker T.

PLoS One. 2016 Jan 5;11(1):e0145615. doi: 10.1371/journal.pone.0145615. eCollection 2016.

10.

Drug trapping in hERG K+ channels: (not) a matter of drug size?

Linder T, Bernsteiner H, Saxena P, Bauer F, Erker T, Timin E, Hering S, Stary-Weinzinger A.

Medchemcomm. 2016 Mar 1;7(3):512-518. doi: 10.1039/c5md00443h. Epub 2015 Dec 22.

11.

Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.

Wanek T, Römermann K, Mairinger S, Stanek J, Sauberer M, Filip T, Traxl A, Kuntner C, Pahnke J, Bauer F, Erker T, Löscher W, Müller M, Langer O.

Mol Pharm. 2015 Sep 8;12(9):3214-25. doi: 10.1021/acs.molpharmaceut.5b00168. Epub 2015 Aug 3.

12.

Structure-activity relationships of bumetanide derivatives: correlation between diuretic activity in dogs and inhibition of the human NKCC2A transporter.

Lykke K, Töllner K, Römermann K, Feit PW, Erker T, MacAulay N, Löscher W.

Br J Pharmacol. 2015 Sep;172(18):4469-4480. doi: 10.1111/bph.13231. Epub 2015 Aug 4.

13.

Discovery of small molecules with vasodilating characteristics and adjustable hydrolytic behavior.

Brunhofer-Bolzer G, Gabriel M, Studenik CR, Erker T.

Bioorg Med Chem. 2015 Aug 1;23(15):4710-8. doi: 10.1016/j.bmc.2015.05.049. Epub 2015 Jun 5.

PMID:
26072172
14.

Enhanced Antiproliferative and Pro-apoptotic Activities of a Novel Curcumin-related Compound in Jurkat Leukemia T-Cells.

Goldhahn K, Hintersteininger M, Steiner G, Erker T, Kloesch B.

Anticancer Res. 2015 May;35(5):2675-80.

PMID:
25964545
15.

Hydrogen sulphide induces HIF-1α and Nrf2 in THP-1 macrophages.

Lohninger L, Tomasova L, Praschberger M, Hintersteininger M, Erker T, Gmeiner BM, Laggner H.

Biochimie. 2015 May;112:187-95. doi: 10.1016/j.biochi.2015.03.009. Epub 2015 Mar 18.

PMID:
25795259
16.

SAR-guided development and characterization of a potent antitumor compound toward B-cell neoplasms with no detectable cytotoxicity toward healthy cells.

Brunhofer-Bolzer G, Le T, Dyckmanns N, Knaus HA, Pausz C, Freund P, Jäger U, Erker T, Vanura K.

J Med Chem. 2015 Feb 12;58(3):1244-53. doi: 10.1021/jm501848m. Epub 2015 Jan 20.

PMID:
25562417
17.

Bumetanide is not capable of terminating status epilepticus but enhances phenobarbital efficacy in different rat models.

Töllner K, Brandt C, Erker T, Löscher W.

Eur J Pharmacol. 2015 Jan 5;746:78-88. doi: 10.1016/j.ejphar.2014.10.056. Epub 2014 Nov 11.

PMID:
25445051
18.

Resveratrol post-transcriptionally regulates pro-inflammatory gene expression via regulation of KSRP RNA binding activity.

Bollmann F, Art J, Henke J, Schrick K, Besche V, Bros M, Li H, Siuda D, Handler N, Bauer F, Erker T, Behnke F, Mönch B, Härdle L, Hoffmann M, Chen CY, Förstermann U, Dirsch VM, Werz O, Kleinert H, Pautz A.

Nucleic Acids Res. 2014 Nov 10;42(20):12555-69. doi: 10.1093/nar/gku1033. Epub 2014 Oct 28.

19.

Efficient modulation of γ-aminobutyric acid type A receptors by piperine derivatives.

Schöffmann A, Wimmer L, Goldmann D, Khom S, Hintersteiner J, Baburin I, Schwarz T, Hintersteininger M, Pakfeifer P, Oufir M, Hamburger M, Erker T, Ecker GF, Mihovilovic MD, Hering S.

J Med Chem. 2014 Jul 10;57(13):5602-19. doi: 10.1021/jm5002277. Epub 2014 Jun 27.

20.

A novel prodrug-based strategy to increase effects of bumetanide in epilepsy.

Töllner K, Brandt C, Töpfer M, Brunhofer G, Erker T, Gabriel M, Feit PW, Lindfors J, Kaila K, Löscher W.

Ann Neurol. 2014 Apr;75(4):550-62. doi: 10.1002/ana.24124. Epub 2014 Apr 2.

PMID:
24615913
21.

Synthesis, biological evaluation and 3D-QSAR studies of new chalcone derivatives as inhibitors of human P-glycoprotein.

Parveen Z, Brunhofer G, Jabeen I, Erker T, Chiba P, Ecker GF.

Bioorg Med Chem. 2014 Apr 1;22(7):2311-9. doi: 10.1016/j.bmc.2014.02.005. Epub 2014 Feb 15.

PMID:
24613626
22.

GABAA receptor modulation by piperine and a non-TRPV1 activating derivative.

Khom S, Strommer B, Schöffmann A, Hintersteiner J, Baburin I, Erker T, Schwarz T, Schwarzer C, Zaugg J, Hamburger M, Hering S.

Biochem Pharmacol. 2013 Jun 15;85(12):1827-36. doi: 10.1016/j.bcp.2013.04.017. Epub 2013 Apr 25.

23.

Foam cell specific LXRα ligand.

Feldmann R, Geikowski A, Weidner C, Witzke A, Kodelja V, Schwarz T, Gabriel M, Erker T, Sauer S.

PLoS One. 2013;8(2):e57311. doi: 10.1371/journal.pone.0057311. Epub 2013 Feb 25.

24.

Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study.

Bankstahl JP, Bankstahl M, Römermann K, Wanek T, Stanek J, Windhorst AD, Fedrowitz M, Erker T, Müller M, Löscher W, Langer O, Kuntner C.

Drug Metab Dispos. 2013 Apr;41(4):754-62. doi: 10.1124/dmd.112.049148. Epub 2013 Jan 10.

PMID:
23305710
25.

Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography.

Bauer F, Wanek T, Mairinger S, Stanek J, Sauberer M, Kuntner C, Parveen Z, Chiba P, Müller M, Langer O, Erker T.

Eur J Pharmacol. 2012 Dec 5;696(1-3):18-27. doi: 10.1016/j.ejphar.2012.09.013. Epub 2012 Sep 26.

26.

A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier.

Wanek T, Kuntner C, Bankstahl JP, Mairinger S, Bankstahl M, Stanek J, Sauberer M, Filip T, Erker T, Müller M, Löscher W, Langer O.

J Cereb Blood Flow Metab. 2012 Nov;32(11):2002-11. doi: 10.1038/jcbfm.2012.112. Epub 2012 Jul 25.

27.

The exploration of thienothiazines as selective butyrylcholinesterase inhibitors.

Karlsson D, Fallarero A, Brunhofer G, Mayer C, Prakash O, Mohan CG, Vuorela P, Erker T.

Eur J Pharm Sci. 2012 Aug 30;47(1):190-205. doi: 10.1016/j.ejps.2012.05.014. Epub 2012 Jun 6.

PMID:
22683890
28.

The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: a positron emission tomography study.

Mairinger S, Bankstahl JP, Kuntner C, Römermann K, Bankstahl M, Wanek T, Stanek J, Löscher W, Müller M, Erker T, Langer O.

Epilepsy Res. 2012 Jun;100(1-2):93-103. doi: 10.1016/j.eplepsyres.2012.01.012. Epub 2012 Feb 17.

29.

Identification and characterization of diarylimidazoles as hybrid inhibitors of butyrylcholinesterase and amyloid beta fibril formation.

Karlsson D, Fallarero A, Brunhofer G, Guzik P, Prinz M, Holzgrabe U, Erker T, Vuorela P.

Eur J Pharm Sci. 2012 Jan 23;45(1-2):169-83. doi: 10.1016/j.ejps.2011.11.004. Epub 2011 Nov 16.

PMID:
22108346
30.

A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.

Wanek T, Kuntner C, Bankstahl JP, Bankstahl M, Stanek J, Sauberer M, Mairinger S, Strommer S, Wacheck V, Löscher W, Erker T, Müller M, Langer O.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):149-59. doi: 10.1007/s00259-011-1941-7. Epub 2011 Oct 8.

31.

PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo.

Mairinger S, Erker T, Muller M, Langer O.

Curr Drug Metab. 2011 Oct;12(8):774-92. Review.

32.

Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein.

Dörner B, Kuntner C, Bankstahl JP, Wanek T, Bankstahl M, Stanek J, Müllauer J, Bauer F, Mairinger S, Löscher W, Miller DW, Chiba P, Müller M, Erker T, Langer O.

Bioorg Med Chem. 2011 Apr 1;19(7):2190-8. doi: 10.1016/j.bmc.2011.02.039. Epub 2011 Feb 26.

33.

The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial multidrug resistance by increasing intracellular drug concentration.

Leitner I, Nemeth J, Feurstein T, Abrahim A, Matzneller P, Lagler H, Erker T, Langer O, Zeitlinger M.

J Antimicrob Chemother. 2011 Apr;66(4):834-9. doi: 10.1093/jac/dkq526. Epub 2011 Jan 19.

PMID:
21393173
34.

A journey from benzanilides to dithiobenzanilides: Synthesis of selective spasmolytic compounds.

Brunhofer G, Granig WH, Studenik CR, Erker T.

Bioorg Med Chem. 2011 Jan 15;19(2):994-1001. doi: 10.1016/j.bmc.2010.11.043. Epub 2010 Nov 25.

PMID:
21185194
35.

Trapping and dissociation of propafenone derivatives in HERG channels.

Windisch A, Timin E, Schwarz T, Stork-Riedler D, Erker T, Ecker G, Hering S.

Br J Pharmacol. 2011 Apr;162(7):1542-52. doi: 10.1111/j.1476-5381.2010.01159.x.

36.

Resveratrol blocks Akt activation in angiotensin II- or EGF-stimulated vascular smooth muscle cells in a redox-independent manner.

Schreiner CE, Kumerz M, Gesslbauer J, Schachner D, Joa H, Erker T, Atanasov AG, Heiss EH, Dirsch VM.

Cardiovasc Res. 2011 Apr 1;90(1):140-7. doi: 10.1093/cvr/cvq355. Epub 2010 Nov 10.

37.

Interaction of diltiazem with an intracellularly accessible binding site on Ca(V)1.2.

Shabbir W, Beyl S, Timin EN, Schellmann D, Erker T, Hohaus A, Hockerman GH, Hering S.

Br J Pharmacol. 2011 Mar;162(5):1074-82. doi: 10.1111/j.1476-5381.2010.01091.x.

38.

Synthesis, spasmolytic activity and structure-activity relationship study of a series of polypharmacological thiobenzanilides.

Brunhofer G, Studenik C, Ecker GF, Erker T.

Eur J Pharm Sci. 2011 Jan 18;42(1-2):37-44. doi: 10.1016/j.ejps.2010.10.005. Epub 2010 Oct 20.

PMID:
20969955
39.

Valerenic acid derivatives as novel subunit-selective GABAA receptor ligands - in vitro and in vivo characterization.

Khom S, Strommer B, Ramharter J, Schwarz T, Schwarzer C, Erker T, Ecker GF, Mulzer J, Hering S.

Br J Pharmacol. 2010 Sep;161(1):65-78. doi: 10.1111/j.1476-5381.2010.00865.x.

40.

Using structural and mechanistic information to design novel inhibitors/substrates of P-glycoprotein.

Klepsch F, Stockner T, Erker T, Müller M, Chiba P, Ecker GF.

Curr Top Med Chem. 2010;10(17):1769-74. Review.

PMID:
20645918
41.

Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.

Bauer F, Kuntner C, Bankstahl JP, Wanek T, Bankstahl M, Stanek J, Mairinger S, Dörner B, Löscher W, Müller M, Erker T, Langer O.

Bioorg Med Chem. 2010 Aug 1;18(15):5489-97. doi: 10.1016/j.bmc.2010.06.057. Epub 2010 Jun 22.

42.

Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate.

Mairinger S, Langer O, Kuntner C, Wanek T, Bankstahl JP, Bankstahl M, Stanek J, Dörner B, Bauer F, Baumgartner C, Löscher W, Erker T, Müller M.

Nucl Med Biol. 2010 Jul;37(5):637-44. doi: 10.1016/j.nucmedbio.2010.02.008. Epub 2010 Apr 8.

43.

Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication.

Stankiewicz-Drogoń A, Dörner B, Erker T, Boguszewska-Chachulska AM.

J Med Chem. 2010 Apr 22;53(8):3117-26. doi: 10.1021/jm901741p.

PMID:
20337460
44.

Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier.

Dörner B, Kuntner C, Bankstahl JP, Bankstahl M, Stanek J, Wanek T, Stundner G, Mairinger S, Löscher W, Müller M, Langer O, Erker T.

J Med Chem. 2009 Oct 8;52(19):6073-82. doi: 10.1021/jm900940f.

45.

Pros and cons of using resazurin staining for quantification of viable Staphylococcus aureus biofilms in a screening assay.

Sandberg ME, Schellmann D, Brunhofer G, Erker T, Busygin I, Leino R, Vuorela PM, Fallarero A.

J Microbiol Methods. 2009 Jul;78(1):104-6. doi: 10.1016/j.mimet.2009.04.014. Epub 2009 May 8.

PMID:
19427338
46.

Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells.

Bernhaus A, Ozsvar-Kozma M, Saiko P, Jaschke M, Lackner A, Grusch M, Horvath Z, Madlener S, Krupitza G, Handler N, Erker T, Jaeger W, Fritzer-Szekeres M, Szekeres T.

Invest New Drugs. 2009 Oct;27(5):393-401. doi: 10.1007/s10637-008-9183-7. Epub 2008 Oct 8.

PMID:
18841326
47.

Novel resveratrol analogs induce apoptosis and cause cell cycle arrest in HT29 human colon cancer cells: inhibition of ribonucleotide reductase activity.

Saiko P, Pemberger M, Horvath Z, Savinc I, Grusch M, Handler N, Erker T, Jaeger W, Fritzer-Szekeres M, Szekeres T.

Oncol Rep. 2008 Jun;19(6):1621-6.

PMID:
18497974
48.

Benzanilides with spasmolytic activity: chemistry, pharmacology, and SAR.

Brunhofer G, Handler N, Leisser K, Studenik CR, Erker T.

Bioorg Med Chem. 2008 Jun 1;16(11):5974-81. doi: 10.1016/j.bmc.2008.04.057. Epub 2008 Apr 26.

PMID:
18477510
49.

Synthesis and biological activity of thienodiltiazem in isolated heart muscle preparations of guinea pigs.

Handler N, Erker T, Lemmens-Gruber R, Studenik CR.

Arzneimittelforschung. 2007;57(12):757-61. doi: 10.1055/s-0031-1296676.

PMID:
18380407
50.

Stilbene analogues affect cell cycle progression and apoptosis independently of each other in an MCF-7 array of clones with distinct genetic and chemoresistant backgrounds.

Bader Y, Madlener S, Strasser S, Maier S, Saiko P, Stark N, Popescu R, Huber D, Gollinger M, Erker T, Handler N, Szakmary A, Jäger W, Kopp B, Tentes I, Fritzer-Szekeres M, Krupitza G, Szekeres T.

Oncol Rep. 2008 Mar;19(3):801-10.

PMID:
18288419

Supplemental Content

Support Center